These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 1658965)

  • 1. Elements from in vitro studies that help understand the action of heparins.
    Hemker HC; Bendetowicz AV; Béguin S
    Thromb Res Suppl; 1991; 14():1-10. PubMed ID: 1658965
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ratios of anti-factor Xa to antithrombin activities of heparins as determined in recalcified human plasma.
    Schoen P; Lindhout T; Hemker HC
    Br J Haematol; 1992 Jun; 81(2):255-62. PubMed ID: 1322691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An approach to assigning in vitro potency to unfractionated and low molecular weight heparins based on the inhibition of prothrombin activation and catalysis of thrombin inhibition.
    Ofosu FA; Smith LM; Anvari N; Blajchman MA
    Thromb Haemost; 1988 Oct; 60(2):193-8. PubMed ID: 2851191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Determination of the levels of unfractionated and low-molecular-weight heparins in plasma: their effect on thrombin-mediated feedback reactions in vivo. Preliminary results after subcutaneous injection.
    Hemker HC; Béguin S; Bendetowicz AV; Wielders S
    Haemostasis; 1991; 21(4):258-72. PubMed ID: 1665467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mode of action of unfractionated and low molecular weight heparins on the generation of thrombin in plasma.
    Hemker HC; Béguin S
    Haemostasis; 1990; 20 Suppl 1():81-92. PubMed ID: 1964667
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The activity of unfractionated heparin and low molecular weight heparins in rabbit plasma--the need for using absolute anti-factor Xa and antithrombin activities.
    Peyrou V; Béguin S; Boneu B; Hemker HC
    Thromb Haemost; 1997 Feb; 77(2):312-6. PubMed ID: 9157588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanisms of action of low molecular weight heparins and heparinoids.
    Ofosu FA; Barrowcliffe TW
    Baillieres Clin Haematol; 1990 Jul; 3(3):505-29. PubMed ID: 1703023
    [No Abstract]   [Full Text] [Related]  

  • 8. Inhibition of thrombin generation by heparin and low molecular weight (LMW) heparins in the absence and presence of platelet factor 4 (PF4).
    Padilla A; Gray E; Pepper DS; Barrowcliffe TW
    Br J Haematol; 1992 Oct; 82(2):406-13. PubMed ID: 1329921
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heparin and low molecular weight heparins inhibit prothrombinase formation but not its activity in plasma.
    Ofosu FA; Lormeau JC; Craven S; Dewar L; Anvari N
    Thromb Haemost; 1994 Dec; 72(6):862-8. PubMed ID: 7740455
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mode of action of CY216 and CY222 in plasma.
    Béguin S; Wielders S; Lormeau JC; Hemker HC
    Thromb Haemost; 1992 Jan; 67(1):33-41. PubMed ID: 1319616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low molecular weight heparins: antithrombotic and haemorrhagic effects and standardization.
    Barrowcliffe TW; Thomas DP
    Acta Chir Scand Suppl; 1988; 543():57-64. PubMed ID: 2847459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative studies of heparin cofactor activity toward antithrombin III and heparin cofactor II, and antithrombin III affinity between low molecular weight heparin and unfractionated heparin.
    Shimotori T; Sakuragawa N
    Semin Thromb Hemost; 1990 Oct; 16 Suppl():71-6. PubMed ID: 1962909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Study of anticoagulant mechanism of low molecular weight heparin.
    Hamano S; Nishiyama M; Komatsu H; Miyata H; Ikeda S; Sakuragawa N
    Thromb Res; 1992 Mar; 65(6):801-8. PubMed ID: 1321995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monitoring low molecular weight heparins at therapeutic levels: dose-responses of, and correlations and differences between aPTT, anti-factor Xa and thrombin generation assays.
    Thomas O; Lybeck E; Strandberg K; Tynngård N; Schött U
    PLoS One; 2015; 10(1):e0116835. PubMed ID: 25625201
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative inhibition of LPS-activated human monocyte-induced thrombin generation by unfractionated heparin and low molecular weight heparins.
    Nguyên P; Rémy MG; Potron G
    Haemostasis; 1999; 29(6):301-9. PubMed ID: 10844403
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of a new one-stage clotting assay for heparin and low molecular weight heparins.
    Harenberg J
    J Mal Vasc; 1987; 12 Suppl B():68-70. PubMed ID: 2834495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heparin sensitivity and resistance in the neonate: an explanation.
    Vieira A; Berry L; Ofosu F; Andrew M
    Thromb Res; 1991 Jul; 63(1):85-98. PubMed ID: 1658964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms for the antithrombotic activity in man of low molecular weight heparins (LMWHs).
    Samama MM; Bara L; Gerotziafas GT
    Haemostasis; 1994; 24(2):105-17. PubMed ID: 7959358
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PiCT
    Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W
    J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of an amidolytic test for comparative calibration of HMW- and LMW-heparins.
    Münstedt K; Bleyl H; Róka L
    Thromb Res; 1991 Oct; 64(1):23-31. PubMed ID: 1663665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.